Mundipharma Breakfast Symposium – Naloxone: New nasal spray formulation and improving access to a lifesaving drug
|Date:||Monday 5 November 2018|
|Time:||7:15am - 08:15am|
|Dr Brian Muller|
Medical Director, Mundipharma
|A new nasal spray formulation for opioid overdose
Mundipharma recently welcomed the TGA registration of Nyxoid® (naloxone 1.8mg) nasal spray. Please join us as we explain the data behind the new intranasal naloxone device.
|Dr James Petty|
Policy Officer, Penington Institute
|Saving lives: Australian naloxone access model
Penington Institute has examined international take-home naloxone (THN) programs to inform the development of a model for the Australian context. These programs distribute the life-saving drug naloxone to people likely to witness an opioid overdose, usually free-of-charge. These findings assisted in proposing a model for a national THN program for Australia to adopt as part of a national public health response to growing rates of opioid overdose.
Nyxoid nasal spray is Schedule 3 medication. To comply with The Therapeutic Goods Act, this symposium is restricted to health care professionals only.
Cost: Complimentary for conference delegates.
This symposium is sponsored by Mundipharma Pty Limited AU-4863 Oct 18